<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757740</url>
  </required_header>
  <id_info>
    <org_study_id>D240</org_study_id>
    <nct_id>NCT04757740</nct_id>
  </id_info>
  <brief_title>Comparison Between Platelet-rich Fibrin and Steroid for Intra-articular Injection for Sacroiliac Joint Dysfunction</brief_title>
  <official_title>Autologous Platelet Rich Fibrin Versus Steroid in Ultrasound-Guided Sacroiliac Joint Injection for Joint Dysfunction (Randomized Comparative Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fayoum University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fayoum University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low back pain is one of the commonest complaints nowadays affecting nearly 20% of the&#xD;
      population, Sacroiliac joint has been accused of being the primary cause of pain in about&#xD;
      10%: 27% of this population.&#xD;
&#xD;
      The sure diagnosis of sacroiliac joint pain is challenging because of multiple crossed&#xD;
      factors of facet joint pain and intervertebral disc pain. Diagnosis can be done by history&#xD;
      taking, local examination, imaging techniques, and controlled local anesthetic blocks.&#xD;
&#xD;
      Controlled local anesthetic blocks are diagnostic and therapeutic done by various methods&#xD;
      either landmark-guided or imaging-assisted either by fluoroscopy, computed tomography (CT),&#xD;
      magnetic resonance (MRI), or ultrasound-guided.&#xD;
&#xD;
      Lower cost, real-time viewing of needle leading to higher accuracy rate, and low ionizing&#xD;
      radiation dose are favoring ultrasound-guided injection over other modalities.&#xD;
&#xD;
      Numerous treatment modalities are being used for sacroiliac joint pain ranging from&#xD;
      physiotherapy and systemic analgesics like Non-steroidal anti-inflammatory drugs (NSAIDs) to&#xD;
      minimally invasive intra-articular, periarticular injection, radiofrequency neurotomy, and&#xD;
      surgical fusion of the joint.&#xD;
&#xD;
      Multiple injectates are being used for intraarticular injection most commonly local&#xD;
      anesthetics and steroids which offer short-term symptomatic relief and delay the degenerative&#xD;
      process.&#xD;
&#xD;
      The need for a longer duration effect directly affects the disease process itself aiming for&#xD;
      accelerating the joint healing rate by biological growth factors found in human blood&#xD;
      especially in platelets.&#xD;
&#xD;
      Platelet-rich plasma (PRP) has been used aiming to inject a high concentration of growth&#xD;
      factors directly into the joint.&#xD;
&#xD;
      Platelet-rich fibrin (PRF), the second generation of platelet-rich plasma is now tried having&#xD;
      the advantage of a simpler preparation and higher values of growth factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient preparation:&#xD;
&#xD;
      History taking, physical examination, provocation tests (Gaenslen's test, Patrick's test, and&#xD;
      Compression &amp; distraction test), and investigations will be done according to the local&#xD;
      protocol designed to evaluate these patients. This includes complete blood count, random&#xD;
      blood glucose, serum creatinine &amp; electrolytes, liver function tests, coagulation profile,&#xD;
      and electrocardiogram (ECG).&#xD;
&#xD;
      Before the intervention, the participants will be informed about the visual analog scale&#xD;
      (VAS) pain score (0-100 mm) (where 0=no pain and 100 = worst comprehensible pain) and the&#xD;
      details of the procedures.&#xD;
&#xD;
      The patient will receive Midazolam 2 mg intravenous (IV) as a premedication. Intravenous&#xD;
      access will be obtained with a 20-gauge intravenous (IV) cannula and monitors (pulse&#xD;
      oximeter, electrocardiography, non-invasive blood pressure) will be applied.&#xD;
&#xD;
      We will use a high-frequency ultrasound probe .and a 22-gauge, 50 mm echogenic needle for&#xD;
      performing the injection.&#xD;
&#xD;
      Injectable platelet-rich fibrin (iPRF) preparation:&#xD;
&#xD;
      blood collection will be done from the patient on the day of intervention in a 9 ml blank&#xD;
      tube. Within maximum 2:3minutes from sampling, it will be placed in the horizontal centrifuge&#xD;
      for a low-speed centrifuge for 8 minutes at 600 rpm 44 g. Upon termination of this process,&#xD;
      the Orange color area in the tube (i-PRF) and the remaining blood materials below will be&#xD;
      noticed. Then, the tubes will be opened cautiously to avoid remixing, 2.5 ml of i-PRF will be&#xD;
      collected from the tubes using a 5ml syringe.&#xD;
&#xD;
      Ultrasound-guided technique:&#xD;
&#xD;
      The patient will be positioned in a prone position over a cushion and after -sterilization&#xD;
      with povidone-iodine and draping, the probe will be positioned transversely over the 5th&#xD;
      lumber spinous process then moving the probe downwards until sacrum can be identified. Then&#xD;
      moving the probe slightly lateral till identifying the 1st posterior sacral foramina (seen as&#xD;
      a break in the hyperechoic contour of the sacral wing) then moving the probe downwards till&#xD;
      the 2nd posterior sacral foramina will be identified. Tilting the lateral part of the probe&#xD;
      slightly upwards and visualizing lateral sacral crest, sacroiliac joint, and iliac bone.&#xD;
      Using color Doppler to ensure the absence of vascularization at the injection site of the&#xD;
      joint (if present moving the probe cranially or caudally until disappearance). after&#xD;
      anesthetizing the skin with 2 ml of 2% lidocaine, the needle will be advanced in-plane to the&#xD;
      joint and 0.1 ml of sterile water will be injected to ensure spread into sacroiliac joint by&#xD;
      unidirectional flow with Color Doppler box then the 3.5 ml of 1% lidocaine and PRF mixture&#xD;
      will be injected in the group (P) or 40 mg of methylprednisolone acetate (Depo-Medrol,&#xD;
      Pfizer) (1 ml) and 1% lidocaine (2.5 ml) in the group (S).&#xD;
&#xD;
      Post-procedural care:&#xD;
&#xD;
      The Patient will be transferred to post-intervention care unit for 2 hours after the&#xD;
      procedure monitoring heart rate, oxygen saturation, and any possible adverse effect then&#xD;
      patients will be discharged to home with a prescription of Diclofenac potassium 50 mg tab&#xD;
      three times daily (TID), diclofenac diethylamine gel topically TID and baclofen 10 mg tab&#xD;
      TID.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain assessment by VAS score</measure>
    <time_frame>1 month after procedure</time_frame>
    <description>the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain assessment by VAS score</measure>
    <time_frame>5 minutes after procedure</time_frame>
    <description>the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment by VAS score</measure>
    <time_frame>1 week after procedure</time_frame>
    <description>the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment by VAS score</measure>
    <time_frame>3 month after procedure</time_frame>
    <description>the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment by VAS score</measure>
    <time_frame>6 month after procedure</time_frame>
    <description>the quality of analgesia between (0-100 mm) where 0=no pain and 100 = worst comprehensible pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Oswestry Disability Index</measure>
    <time_frame>1 month after procedure</time_frame>
    <description>to assess level of disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Oswestry Disability Index</measure>
    <time_frame>6 month after procedure</time_frame>
    <description>to assess level of disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with procedure</measure>
    <time_frame>1 month after procedure</time_frame>
    <description>Will be evaluated according to a satisfaction score (poor = 0; fair = 1; good = 2; excellent= 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient discomfort with procedure</measure>
    <time_frame>5 minutes after procedure</time_frame>
    <description>yes or no question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematoma</measure>
    <time_frame>5 minutes after procedure</time_frame>
    <description>procedure related complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergy</measure>
    <time_frame>10 minutes after procedure</time_frame>
    <description>procedure related complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age</measure>
    <time_frame>5 minutes before procedure</time_frame>
    <description>In years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight</measure>
    <time_frame>5 minutes before procedure</time_frame>
    <description>In kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>5 minutes before procedure</time_frame>
    <description>In meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>5 minutes before procedure</time_frame>
    <description>In kilogram per square meter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic requirement after injection</measure>
    <time_frame>1 day after procedure</time_frame>
    <description>analgesic dose needed after procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Platelet rich fibrin Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Platelet rich fibrin. Group P</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylprednisolone acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group S</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intra-articular Platelet rich fibrin and lidocaine</intervention_name>
    <description>intra-articular injection of 3.5 ml of 1% lidocaine and PRF mixture.</description>
    <arm_group_label>Platelet rich fibrin Group</arm_group_label>
    <other_name>Platelet rich fibrin Group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone acetate and lidocaine</intervention_name>
    <description>intra-articular injection of Mixture of 40 mg of methylprednisolone acetate(1 ml) and 1% lidocaine (2.5 ml). intra-articular steroid</description>
    <arm_group_label>Methylprednisolone acetate</arm_group_label>
    <other_name>Steroid group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient aged &gt;18 years with Low back pain &gt; 6 months.&#xD;
&#xD;
          2. Failure of conservative treatment for 3 months.&#xD;
&#xD;
          3. Positive findings on at least one of three provocation tests for sacroiliac joint&#xD;
             pain: Gaenslen's test, Patrick's test, and compression &amp; distraction test.&#xD;
&#xD;
          4. Positive diagnostic injection (pain reduction &gt;80% after injection).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient refusal.&#xD;
&#xD;
          2. Disorders in the hip joint.&#xD;
&#xD;
          3. Signs of lumbar radiculopathy.&#xD;
&#xD;
          4. Bleeding disorders including anticoagulation medications.&#xD;
&#xD;
          5. Positive response to Kemp's test (pain provocation test for sciatica).&#xD;
&#xD;
          6. Infection at site of injection.&#xD;
&#xD;
          7. Psychiatric problems as prevent completion of the study related questionnaires.&#xD;
&#xD;
          8. Morbid obesity BMI &gt; 40.&#xD;
&#xD;
          9. Severe cardiac and respiratory disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed A Alsaeid, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fayoum University Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amr H Mahmoud, Msc</last_name>
    <phone>00201004349592</phone>
    <email>Ah1240@FAYOUM.EDU.EG</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maged L Bolous, MD</last_name>
    <phone>00201222468054</phone>
    <email>mlb00@fayoum.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fayoum University hospital</name>
      <address>
        <city>Madīnat al Fayyūm</city>
        <state>Faiyum Governorate</state>
        <zip>63514</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hany M Yassin, MD.</last_name>
      <phone>1111363602</phone>
      <phone_ext>+20</phone_ext>
      <email>hmy00@fayoum.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Yasser S Mostafa, M.Sc.</last_name>
      <phone>1010509735</phone>
      <phone_ext>+20</phone_ext>
      <email>ysm03@fayoum.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 14, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fayoum University Hospital</investigator_affiliation>
    <investigator_full_name>Amr hamdy Mahmoud</investigator_full_name>
    <investigator_title>Assistant lecturer</investigator_title>
  </responsible_party>
  <keyword>sacroiliac joint</keyword>
  <keyword>platelet rich fibrin</keyword>
  <keyword>ultrasound-guided</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

